Discovery of PARP1-Sparing Inhibitors for Protein ADP-Ribosylation

Authors:

Abstract
Poly-ADP-ribose polymerases (PARPs) that catalyze cellular ADP-ribosylation play important roles in human health. PARP inhibitors have found success in the clinic for cancer treatment. However, isoform-specific inhibitors are needed for improved safety. Here, we report the unexpected discovery of nicotinamide mimics that block non-PARP1-catalyzed ADP-ribosylation at micromolar concentrations. These PARP1-sparing PARP inhibitors represent first-in-class probes for ADP-ribosylation, shedding light on the selective inhibition of PARPs.
Funding Information
  • National Cancer Institute (R01CA276240)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB031830)
  • National Institute of General Medical Sciences (R35GM137901)

This publication has 37 references indexed in Scilit: